| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Headquartered in New Delhi, Ranbaxy Laboratories was established in 1961,
becoming a public company in 1973. This report provides an insight into the
company, reviewing its current business structure and activities.
Ranbaxy has grown to become the largest domestic pharmaceutical firm in India,
with a market share of 4.85% (MAT July 2003) and was ranked ninth amongst the
generic markets in the US. The company has a ground presence in 34 countries,
and exports its products to over 100 countries. It has manufacturing
facilities in seven countries: China, India, Ireland, Malaysia, Nigeria, the
United States, and Vietnam. The company's business also includes animal
health, fine chemicals and diagnostics.
The growth strategy that Ranbaxy has adopted is one of internationalisation
and of enhancing its own domestic market share. The company has an expanding
international portfolio of affiliates, joint ventures and representative
offices across the globe with subsidiaries in the US, UK, Germany, France,
China, Brazil and South Africa. The company's first joint venture was set up
in Lagos, Nigeria, in 1977. More recently, the company acquired the German
generics business of Bayer in 2000, naming the unit Basics, and in the same
year the company made its first ventures into the Brazilian market. In 2001,
Ranbaxy set up a new manufacturing facility in Vietnam, with an investment
worth US$10 million. Additionally, the company has entered into marketing
agreements with companies such as Eli Lilly in India, and Bayer, with a
worldwide agreement regarding a once-daily version of ciproxfloxacin,
originally developed by Ranbaxy. The company has also made inroads into the
Middle Eastern market, and has fully developed marketing operations in the
United Arab Emirates, Bahrain and Oman. Additionally, Ranbaxy claims to be the
only Indian company to be registered in Saudi Arabia.
The early part of 2004 was an active period for Ranbaxy as the company's trend
for international growth continued. As of January 2004, Ranbaxy finalised the
acquisition of RPG (Aventis) SA, which is now a wholly owned subsidiary of
Ranbaxy. RPG Aventis was ranked fifth in the French generic market, with sales
of 52 million Euros and a market share of 6%. In February 2004 Ranbaxy
approved the establishment of a subsidiary in Spain.
This report provides information on the company's active product lines and
ANDA approvals, along with a review of major developments, such as M&A
activity, strategic alliances and litigation. The company's most recent
quarterly and annual financial results are illustrated with comparative
figures, charts and a detailed review of the data which allows you to track
the company's progress.
TABLE OF CONTENTS
- EXECUTIVE SUMMARY
- INTRODUCTION
- Subsidiaries of Ranbaxy
- Ranbaxy announces focus on pharmaceuticals business
- Goa plant receives UK MHRA approval.
- Ranbaxy launches in Canada
- Ranbaxy commissions new facility in
- Ranbaxy opens third R&D facility
- PRODUCTS5
- International DMF filings and approvals, January - December 2004
- Ranbaxy ANDA Approvals, 2002-05
- Antiretrovirals
- Ranbaxy forms JV in South Africa to market antiretrovirals
- Recent product approvals
- Voglibose
- Ranbaxy files esomeprazole ANDA
- Gabapentin capsules
- Pseudoephedrine extended-release tabl
- Zidovudine
- Tolterodine tablets (tentative)
- Benazepril and hydrochlorothiazide tablets
- Sumatriptan tablets (tentative
- Glimepiride tablets (tentative)
- Terbinafine (tentative)
- Lamivudine tablets (tentative)
- Clarithromycin
- FINANCIAL RESULTS
- Preliminary Year End Results -- Fiscal 2005 Ended 31st December 2005
- Latest Full Year Highlights, fiscal 2004
- Full Year Results, 2001-04
- Segment Data
- Segment Results, 2002-04
- Geographic Segment Results
- Revenues by Geographic Region (Rs million)
- Sales in Key Markets -- 2004 (US$ mill 18
- Latest Quarter Results, fourth quarter ended 31st December 2005
- MAJOR DEVELOPMENTS
- Mergers, acquisitions and agreements
- Ranbaxy to co-market Ferring's desmopressin in India
- Ranbaxy and Nippon Chemiphar consolidate relationship
- Ranbaxy to market Lupin's TB brands in Africa
- Ranbaxy acquires generic product portfolio from Efarmes
- Ventiv Health and Ranbaxy sign isotretinoin agreement
- GlaxoSmithKline
- RPG (Aventis)
- Merck and Thembalami
- Mallinckrodt Baker
- Medicines for Malaria Venture
- Nippon Chemiphar
- Signature Pharmaceuticals
- Schwarz Pharma
- Veratide
- Wockhardt
- Litigation
- Lipitor
- Pfizer gains preliminary injunction in Finland
- Pfizer defeats Ranbaxy in atorvastatin case
- Ranbaxy and Pfizer take atorvastatin battle to Norway
- Austrian Patent Office issues favourable ruling for Ranbaxy on
atorvastatin, Pfizer to appeal
- Pfizer prevails in challenge to basic Lipitor patent in British High
Court
- Cephalon reaches modafinil litigation settlements with Teva, Ranbaxy
and Mylan
- Pfizer wins preliminary injunction in quinapril case against Ranbaxy,
Teva
- Abbott gains clarithromycin legal victories, but Ranbaxy sees reasons
for optimism
- Ranbaxy comments on simvastatin si
- Ranbaxy files suit against Barr and Tev
- AMR/sanofi-aventis file for injunction against manufacturers of
generic fexofenadine
- Astellas and BI file US lawsuit against Flomax generic
- UK SFO investigation
- UK Department of Health legal action settled
- CONTACT DETAILS
|
